Business
Strategic update on the progress and development of Molecure's key clinical projects in 2024
Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024: Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed
About this update from Molecure Sa
[{"type":"image","alt":"Molecure","displaySize":"","headline":null,"caption":"Molecure","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/19835773f963056624aa92deb3756643"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cGoG3kZbtCsthrJaLub1tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/19835773f963056624aa92deb3756643","width":300,"height":144}},"lazy":false},{"type":"text","content":"Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:","length":245,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.","length":255,"tagName":"p"}]},{"val":[{"type":"text","content":"Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research and projected growth of the MASH market to over $25 billion by 2032. Clinical development of OATD-01 for MASH treatment will be carried out in partnership.","length":303,"tagName":"p"}]},{"val":[{"type":"text","content":"Progress in the first-in-human study of OATD-02, a key oncology program in Phase I, where no dose-limiting toxicity (DLT) has been observed in patients who have received the drug (during dose escalation). Positive recommendation from the Safety Review Committee (SRC) to continue recruitment and to include additional patients at the 20 mg daily dose level. In early 2025, after another positive recommendation from the SRC, Molecure decided to modify the first-in-human study protocol and submitted a request to the relevant authorities and ethics committees to move to higher doses than initially planned for new patients.","length":624,"tagName":"p"}]},{"val":[{"type":"text","content":"Progress in the mRNA-targeted drug platform – two therapeutic targets validated (proof-of-concept in vitro), with a plan to select lead compounds. Mo...